Feature | September 14, 2012

SCAI Launches Cath Lab AUC and Guidelines App

AUC calculator app is latest addition to SCAI Quality Improvement Toolkit

September 14, 2012 — Coronary revascularization appropriate use criteria (AUC) are now just a click away with the new SCAI Quality Improvement Toolkit (SCAI-QIT) AUC and Guidelines App, launched this week by the Society for Cardiovascular Angiography and Interventions (SCAI).

“The new app is a calculator tool that makes it simple to access the AUC on heart revascularization without having to carry around printed documents,” said Kalon Ho, M.D., FSCAI, architect of the new tool. “While we don’t intend for this tool to replace clinical judgment, we do hope it provides easier access to information that can guide the cath lab team’s decisions.”

Once members of the cardiac catheterization lab team input facts about a patient’s case, the app will indicate where a “typical” case with those same characteristics would fall on a spectrum of “appropriate,” “uncertain” or “inappropriate” for revascularization, as defined by the latest recommendations from leading cardiology societies, including SCAI and the American College of Cardiology Foundation, among others. Interventional cardiologists can then use that information to make recommendations for treatment of individual patients’ symptoms and conditions. 

SCAI’s calculator app also recognizes that complete documentation is essential in today’s healthcare environment. The app providers users with key data, including the relevant AUC scenario number, the indication score, a summary of the patient’s case and a link to a printer-friendly reporting sheet that can be added to the patient’s chart.  

In coming months, SCAI will expand the app with new modules to help healthcare providers access interventional cardiology guidelines and additional AUC, including those for diagnostic cardiac catheterization. Plans are also underway for the app to include options for interfacing with electronic health records (EHR), further assisting providers with documentation.

The AUC and Guidelines App is part of the expanded SCAI-QIT developed by SCAI’s Quality Improvement Committee to provide tools and resources that help both facilities and providers deliver consistent quality care to cath lab patients. Currently tools focus on guidelines and AUC, national database participation, inventory management, pre-procedure activities, operator and staff requirements, procedural quality and best practices, as well as facility and environmental issues. Each tool is regularly updated to incorporate the latest guidelines, regulatory requirements and feedback from the many SCAI Quality Champions who are using the tools in cath labs around the world.

“The SCAI-QIT has become an important resource for continuously improving cath lab quality. Within months of its launch, interventional cardiologists began telling us how SCAI-QIT helps them identify and address opportunities for improvement,” said SCAI Immediate Past President Christopher J. White, M.D., FSCAI. “The new AUC Calculator App is an example of a tool that will help cath lab teams easily access information supportive of high-quality, evidence-based patient care.”

The SCAI-QIT was developed with founding support from Daiichi Sankyo Lilly and support from AstraZeneca.

For more information: www.SCAI-QIT.org

Related Content

Synergy stent, abluminal polymer DES, bioresorbable polymer DES, bioresorbable polymer metallic stent

The Synergy stent is the first FDA cleared drug-eluting stent to use a bioresorbable polymer drug carrier. When the polymer dissolves after about four months, the devices become a bare metal stent. The technology is supposed to reduce the rate of late stent thrombosis due to vessel inflammation caused by durable polymers.

Feature | Stents Bioresorbable| January 17, 2017 | Dave Fornell
One of the big advancements in drug-eluting stent (DES) technology has been the development of bioresorbable polymers
Medtronic, CoreValve Evolut R TAVR system, U.S. IDE Study, TCT 2016
News | Heart Valve Technology| November 03, 2016
Medtronic plc unveiled new clinical data showing that patients treated with the self-expanding CoreValve Evolut R...
congenital heart patients, cardiac cath lab, anesthesia sedation practices, joint document, SCAI, SPA, CCAS
News | Congenital Heart| November 03, 2016
The Society for Cardiovascular Angiography and Interventions (SCAI), the Society for Pediatric Anesthesia (SPA) and the...
open-heart surgery, PCI, percutaneous coronary intervention, NOBLE trial, left main coronary artery disease, LMCAD, TCT 2016
News | Cardiovascular Surgery| November 03, 2016
Coronary artery bypass (CABG) surgery is the standard treatment for revascularization in patients with left main...
SENTINEL trial, transcatheter embolic protection, TCEP, TAVR, stroke, TCT 2016
News | Embolic Protection Devices| November 03, 2016
An international study has found that transcatheter cerebral embolic protection (TCEP) is safe, provides effective...
News | Drug-Eluting Balloons| November 03, 2016
The Spectranetics Corp. announced that it has submitted to the U.S. Food & Drug Administration (FDA) its Pre-Market...
RESPECT trial, Amplatzer PFO Occluder, St. Jude Medical, TCT 2016
News | Structural Heart Occluders| November 02, 2016
St. Jude Medical Inc. announced the long-term data from RESPECT, a landmark trial, during a First Report session at the...
Medtronic, Resolute Integrity DES, drug-eluting stent, BIO-RESORT study, TCT 2016
News | Stents Drug Eluting| November 02, 2016
Investigators recently unveiled clinical data from the independent BIO-RESORT study, representing the first all-comers...
Medtronic, Harmony TPV, transcatheter pulmonary valve, clinical study results, TCT 2016
News | Heart Valve Technology| November 02, 2016
Medtronic plc recently announced new clinical data for the Harmony Transcatheter Pulmonary Valve (TPV) from its early...
St. Jude Medical, Amplatzer PFO Occluder, FDA approval, U.S. launch
Technology | Structural Heart Occluders| November 02, 2016
St. Jude Medical Inc. announced this week the U.S. Food and Drug Administration (FDA) approval and launch of the...
Overlay Init